Photo taken from Vivek Subbiah/LinkedIn
Oct 18, 2023, 16:54
Vivek Subbiah: Final efficacy and safety results of the ROAR phase 2 basket trial of dabrafenib in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“BRAFV600E alterations are prevalent across multiple tumors and is a tissue agnostic precision medicine target. Final efficacy and safety results of the ROAR phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers:
- Anaplastic thyroid carcinoma (n = 36),
- Biliary tract cancer (n = 43) adenocarcinoma of the small intestine (n = 3),
- Low-grade glioma (n = 13),
- High-grade glioma (n = 45)
- Hairy cell leukemia (n = 55)
- Multiple myeloma (n = 19).
(both solid+ liquid tumors) – BRAF + Mutiple myeloma as well
Link to Nature Medicine paper.”
Source: Vivek Subbiah/LinkedIn
News Feed
-
Dec 10, 2023, 17:20 | BlogDaniel Blanco: Day 1 of the 2023 St. Jude Global Alliance Convening
-
Dec 10, 2023, 16:59 | InsightYüksel Ürün: MFS continues to be a reliable predictor for overall survival
-
Dec 10, 2023, 16:53 | PositiveMatteo Lambertini: December 7, 2023 …a day to remember
-
Dec 10, 2023, 12:45 | BlogSIOP: Worldwide Candle Lighting Day is a celebration of solidarity and memory
-
Dec 10, 2023, 18:12The Cancer Research Interns (CRI) Summer Program is now accepting applications! - Train at NCI
-
Dec 10, 2023, 18:08Apply for the Basic Research in Cancer Health Disparities Program - NCI Center to Reduce Cancer Health Disparities (CRCHD)
-
Dec 10, 2023, 18:01Giselle Sholler: Our research that led to the FDA-Oncologic Drugs Advisory Committee 70% approval for moving Difluoromethylornithine forward
-
Dec 10, 2023, 16:59Yüksel Ürün: MFS continues to be a reliable predictor for overall survival
-
Dec 10, 2023, 12:03Eleonora Teplinsky: The POSITIVE Trial SABCS23 updates are so important to help with oncofertility counseling
-
Dec 10, 2023, 16:53Matteo Lambertini: December 7, 2023 …a day to remember
-
Dec 8, 2023, 16:33Big thank you to Dr. Rucha Kiran Patil for sharing their experiences and learnings on writing abstracts and poster presentations - Novo Nordisk Haemophilia Foundation
-
Dec 6, 2023, 14:57Tracy Gosselin: Jennifer Petruno Receives DAISY Award for Extraordinary Nurses
-
Dec 3, 2023, 16:34Tedros Adhanom Ghebreyesus: Grateful to Namibia’s Prime Minister Saara Kuugongelwa-Amadhila for her commitment to health
-
Dec 2, 2023, 18:08100 Influential Celebrities in Oncology: The 2023 Edition – Part 5
-
Dec 10, 2023, 05:08Global Summit on War and Cancer: Agenda
-
Dec 4, 2023, 16:26SIOP 2023 by Numbers! - International Society of Paediatric Oncology
-
Dec 2, 2023, 16:43In our recent survey, nearly 1,700 ASCO members shared feedback on the ABIM MOC requirements - ASCO
-
Nov 28, 2023, 17:34The International Association of Cancer Registries annual conference - IARC
-
Nov 26, 2023, 18:05Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
Dec 10, 2023, 17:39Dr. Salami is the winner of the American Urological Association’s prestigious Gold Cystoscope Award - YUO
-
Dec 10, 2023, 17:26Mark Awad was honored by GO2 for Lung Cancer at the 18th Annual Simply the Best Gala - Dana-Farber Cancer Institute
-
Dec 9, 2023, 17:00Wafik S. El-Deiry: Honored to share the news of my election as the Chair of the WIN Consortium in Personalized Cancer Medicine
-
Dec 8, 2023, 17:54Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
-
Dec 8, 2023, 17:35Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity